# US 2009/0275083 A1 · Isolated peptides having phospholipase inhibitory activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275083 A1
- Document ID: US20090275083A1
- Status: Published application
- Kind: A1
- Application number: 12/433,266
- Filed: 2009-04-30
- Published: 2009-11-05
- Earliest claimed: 2008-04-30
- Assignees: Novozymes A/S
- Inventors: Leonardo De Maria; Ming Li; Christian Isak Joergensen; Kim Borch; Tom Anton Busk Nielsen; Jesper Vind
- Web page: https://patentgrep.com/patent/US20090275083A1

## CPC

- C07K 14/37: from fungi
- C12N 9/20: Triglyceride splitting, e.g. by means of lipase
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides for isolated peptides having phospholipase inhibitory activity, polypeptides comprising phospholipase inhibitory activity and lipases capable of being inhibited by the isolated peptides and/or polypeptides comprising phospholipase inhibitory activity. The invention also relates to nucleic acid constructs, recombinant expression vectors, and recombinant host cells comprising the polynucleotides as well as methods for producing and using the peptides and the polypeptides having lipase inhibitory activity.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

An isolated peptide having phospholipase inhibitory activity, selected from the group consisting of:
a) an isolated peptide comprising an amino acid sequence having at least 65% identity to the residues 289-310 of SEQ ID NO: 1 or the residues 154-175 of SEQ ID. NO: 10;
b) an isolated peptide encoded by a polynucleotide that hybridizes under medium stringency conditions or high stringency conditions with a peptide coding sequence of SEQ ID NO: 1 or the complementary stand of said peptide coding sequence of SEQ ID NO: 1;
c) an isolated peptide encoded by a polynucleotide comprising a nucleotide sequence having at least 65% identity to the residues 289-310 of SEQ ID NO: 1; and
d) an isolated peptide comprising a motif with the following amino acid sequence: M1T2D3X4X5L6E7X8K9L10N11X12Y13V14X15X16D17X18E19Y20X21K22 where X4, X5, X8, X12, X15, X16, X18, and X21 independently may be any amino acid, wherein the peptide has a length of less than 60 amino acids (aa).

### Claim 31 (depends on 30)

The peptide of claim 30, which has a length of less than 55 aa.

### Claim 32 (depends on 30)

The peptide of claim 30, which has a length of at least 15 aa.

### Claim 33 (depends on 30)

The peptide of claim 30, having a secondary structure of an alpha helix.

### Claim 34 (depends on 30)

The peptide of claim 30, wherein the amino acid at each of the positions X4, X5, X8, X12, X15, X16, X18, and X21 present in the motif independently are selected whereby X4 is A or E; X5 is E or Q; X8 is K or A; X12 is S or N; X15 is E, Q or A; X16 is L or M; X18 is K or Q; and X21 is I or V.

### Claim 35 (depends on 30)

The peptide of claim 30, which compared to SEQ ID NO: 1 comprises at least one amino acid substitution at a position corresponding to FoL residues D291; L294; E295; K297; L298; N299; Y301; D305; K306; Y308; or V309.

### Claim 36 (depends on 30)

The peptide according to claim 30, which compared to SEQ ID NO: 1 comprises at least one amino acid substitution corresponding to FoL residues D291E; L294A; E295T,S; K297R; L298A; N299D,E; Y301W; D305A; K306R; Y308E,D; or V309,I,N,Q.

### Claim 37 (depends on 30)

An isolated polynucleotide encoding the peptide of claim 30.

### Claim 38 (depends on 37)

A nucleic acid construct comprising the polynucleotide of claim 37 operationally linked to at least one control sequence that directs the production of the peptide in an expression host.

### Claim 39 (depends on 38)

A recombinant expression vector comprising the nucleic acid construct of claim 38.

### Claim 40 (depends on 38, 39)

A recombinant host cell comprising the nucleic acid construct of claim 38 or the recombinant expression vector of claim 39.

### Claim 41 (depends on 30)

A method of preparing the isolated peptide of claim 30 comprising the steps:
a) cultivating a host cell comprising the nucleic acid construct comprising the polynucleotide encoding at least one copy of the peptide under conditions conducive for production of the peptide; and
b) recovering the peptide.

### Claim 42 (depends on 30)

A polypeptide comprising the peptide of claim 30 and a lipase, wherein the lipase has a phospholipase activity below 50 PHLU/mg in a plate assay.

### Claim 43 (depends on 42)

The polypeptide of claim 42 comprising a lipase having at least 70% identity to Thermomyces lanuginosus (SEQ ID NO: 9).

### Claim 44 (depends on 42)

The polypeptide of claim 42 wherein the lipase comprises at least one alteration which independently is an insertion, a deletion or a substitution.

### Claim 45 (depends on 44)

The polypeptide of claim 44 wherein the at least one alteration of the lipase comprises one or more amino acid substitutions corresponding to the residues E87R, I90L, G91T, I202P, R209L, E210I, or T244L of Thermomyces lanuginosus (SEQ ID NO: 9).

### Claim 46 (depends on 44)

The polypeptide of claim 44 wherein the lipase comprises a substitution of the residues corresponding to 248-255 of Thermomyces lanuginosus (SEQ ID NO: 9) with the residues 246-254 of Fusarium oxysporum (SEQ ID NO: 1), or 248-253 of Thermomyces lanuginosus (SEQ ID NO: 9) with the residues 247-252 of Fusarium oxysporum (SEQ ID NO: 1).

### Claim 47 (depends on 30)

A polypeptide having phospholipase inhibitory activity, wherein a protein with at least three solvent accessible residues of an alpha-helix localized at the surface of said protein comprises an alteration in the alpha-helix of at least one of the solvent accessible residues corresponding to position D3, L6, L10, Y13, V14, D17, and X21 and/or the edge residues corresponding to position E7, K9, N11, X18, and Y20 of the motif of claim 30.

### Claim 48 (depends on 47)

The polypeptide of claim 47, wherein the parent protein has an amino acid sequence having at least 70% identity to Plectasin (SEQ ID NO: 11); Monellin (SEQ ID NO: 12); Protegrin (SEQ ID NO: 13); Barnase (SEQ ID NO: 14); Cytostatins (SEQ ID NO: 15); or Apolipoprotein E (SEQ ID NO: 16).

### Claim 49 (depends on 30, 42)

A method of preparing the polypeptide of claim 42 comprising attaching the peptide of claim 30 to a lipase, wherein the lipase has a phospholipase activity below 50 PHLU/mg in a plate assay.

### Claim 50 (depends on 30)

A method of preparing a polypeptide comprising:
a) selecting a protein having an alpha-helix localized at the surface of the protein whereby at least three, at least four, at least five, or at least six residues of said alpha-helix is solvent accessible;
b) aligning the alpha-helix of the protein with the peptide of claim 30;
c) identifying the residues in the alpha-helix of the protein that are solvent accessible corresponding to position D3, L6, L10, Y13, V14, D17, and X21 of the motif of claim 30;
d) altering at least one of the amino acids in the protein identified in step (c);
e) testing the polypeptide for phospholipase inhibitory activity;
f) selecting the polypeptide having phospholipase inhibitory activity; and
g) producing the polypeptide selected in (f).

### Claim 51 (depends on 1, 50)

The method of claim 50 further comprising identifying in step (c) the residues in the alpha-helix of the protein that are potentially solvent accessible corresponding to position E7, K9, N11, X18, and Y20 of the motif of claim 1.

### Claim 52 (depends on 51)

The method of claim 51 further comprising a step of making at least one alteration at one or more positions in the protein.

### Claim 53 (depends on 30, 47)

A lipase having a phospholipase activity below 50 PHLU/mg in a plate assay which is capable of being inhibited by the peptide according to claim 30, wherein said lipase comprises at least one alteration which independently is an insertion, a deletion or a substitution, whereby the activity of said lipase is inhibited upon binding of at least one of (a) the isolated peptide having phospholipase inhibitory activity according to claim 30; or (b) the peptide having phospholipase inhibitory activity comprised in the polypeptide according to claim 47.

### Claim 54 (depends on 53)

The lipase of claim 53, having at least 70% identity to Thermomyces lanuginosus (SEQ ID. NO: 9).

### Claim 55 (depends on 54)

The lipase of claim 54, having at least one alteration which is a substitution corresponding to the residues L92; R96; L203; I207; R211; L243; L250; or L252 of Thermomyces lanuginosus (SEQ ID NO: 9).

### Claim 56 (depends on 55)

The lipase of claim 55, wherein the at least one alteration is a substitution corresponding to the residues L92D,E,W; R96E,D,A; L203W,K,M; I207D,E; R211H; L243W,K L250D,E,R; and L252S,T of Thermomyces lanuginosus (SEQ ID NO: 9).
